drugset
drugset / Trial / NCT05071183

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

NCT05071183 ↗

Phase 1/2 Terminated 9 enrolled Turning Point Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)

Timeline

Start
2021-09-23
Primary completion
2023-03-01
Completion
2023-03-01

Outcome

Outcome not reported

Stopped: “Inability to achieve and optimize a dose that could provide a positive benefit risk profile”

Drugs

EvaluationDrugModalityDoseRoute
Subject Repotrectinib Small molecule — Oral
Subject Trametinib Small molecule — Oral

Indications

metastatic neoplasm